可检测不到微小残留病灶是脾边缘区淋巴瘤独立预后因素
结果显示uMRD患者5年无进展生存和总生存均显著优于MRD阳性患者,且uMRD是PFS的独立良好预后因素,尤其对仅达部分缓解的患者意义突出。
要点
- uMRD患者5年PFS和OS均显著高于MRD阳性患者。
- 仅达PR但uMRD者5年PFS显著优于PR且MRD阳性者。
核心结论
- uMRD是SMZL患者的独立良好预后因素,尤其对仅达PR的患者具有预后价值。
研究设计与样本
- 前瞻性研究纳入71例初治伴骨髓受累的SMZL患者,均接受利妥昔单抗为基础治疗。
临床怎么用
- 对接受利妥昔单抗为基础治疗的SMZL患者,可通过流式细胞术监测骨髓MRD。
- uMRD状态有助于预后分层,尤其对仅达PR的患者可识别预后良好亚群。
局限性
- 样本量71例,结论需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The role of minimal residual disease (MRD) in splenic marginal zone lymphoma (SMZL) has not been well studied. We prospectively designed a study to evaluate undetectable MRD (uMRD) by multiparameter flow cytometry as a prognostic factor. Residual disease level of <0·01% was defined as uMRD. A total of 71 newly diagnosed patients with bone marrow involvement were enrolled and all received rituximab-based therapy. The overall response rate (ORR) was 98·5% (70/71), with a complete remission (CR) rate of 54·9% (39/71). There were a total of 295 MRD detections in bone marrow and 77·4% patients (55/71) had uMRD. The 5-year progression-free survival (PFS) [(74·8 ± 6·5)% vs. (31·4 ± 12·6)%, P < 0·001] and 5-year overall survival (OS) [(87·2 ± 5·6)% vs. (68·9 ± 13·4)%, P = 0·035] were significantly higher in uMRD patients than in MRD-positive patients. The 5-year PFS in partial remission (PR) patients with positive MRD was significantly poorer than that of PR patients with uMRD [(21·1 ± 12·9)% vs. (83·3 ± 8·8)%, P = 0·005]. Multivariate prognostic analysis revealed that uMRD was an independent good prognostic factor for PFS (hazard ratio 0·162, 95% confidence interval 0·041-0·635; P = 0·009). All these results highlight uMRD as an independent prognostic factor in patients with SMZL, especially for patients who only achieve PR.
引用
- Lyu R, Wang T, Wang Y, et al. Undetectable minimal residual disease is an independent prognostic factor in splenic marginal zone lymphoma. Br J Haematol. 2021. PMID: 34328213. doi:10.1111/bjh.17703
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。